Ginsenoside Improve Metabolic Syndrome
Mo kle
Abstrè
Deskripsyon
Methods : A randomized, double-blind, placebo-controlled, single-center study in 60 subjects who are not taking drugs that could affect metabolic and vascular function. Subjects will be randomized into a Korean red ginseng (3.0g/d) group or placebo group for a 4-week study.
We will collect anthropometric measurements, blood for laboratory testing, inflammatory marker, hormones and mitochondrial DNA copy number.
Subject : Older than 40 years of age, presented with metabolic syndrome. Subjects were excluded if they were taking drugs that could affect metabolic and vascular function, including BP control drug, anti-diabetic drugs and lipid-lowering drugs.
Measurement : We will collect anthropometric measurements and blood for laboratory testing at the initial(week 0) and final (week 4)visits. Serum levels of blood glucose, insulin, total cholesterol, HDL-cholesterol,triglyceride, and DNA copy number of mitochondria.
Dat
| Dènye verifye: | 12/31/2013 |
| Premye Soumèt: | 07/20/2013 |
| Enskripsyon Estimasyon Soumèt: | 01/09/2014 |
| Premye afiche: | 01/12/2014 |
| Dènye Mizajou Soumèt: | 01/09/2014 |
| Dènye Mizajou afiche: | 01/12/2014 |
| Dat aktyèl kòmanse etid la: | 01/31/2014 |
| Dat Estimasyon Prensipal Estimasyon an: | 08/31/2014 |
| Dat estime fini etid la: | 11/30/2014 |
Kondisyon oswa maladi
Entèvansyon / tretman
Dietary Supplement: Ginsenoside
Dietary Supplement: Dietary fiber fill
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| Experimental: Ginsenoside Ginsenoside :
Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group | Dietary Supplement: Ginsenoside 3.0 g/ d for 28 days |
| Placebo Comparator: Dietary fiber fill Dietary fiber fill manufactured to mimic Ginsenoside tablet | Dietary Supplement: Dietary fiber fill 3g/day, 28days |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 40 Years Pou 40 Years |
| Sèks ki kalifye pou etid | All |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: - metabolic syndrome Exclusion Criteria: - Taking drug for lipid-lowering, BP control and anti-diabetic. |
Rezilta
Mezi Rezilta Prensipal yo
1. Change from baseline in metabolic syndrome profile at week 4 [Baseline and 4 weeks from intake of Ginsenoside]
Mezi Rezilta Segondè
1. Change from baseline in hormones at week 4. [Initial and 4 weeks later]
Lòt Mezi Rezilta
1. Mitochondria DNA copy number [initial and 4 weeks later]
